Canaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $114 to $106.
Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $114 to $106.